Abstract: A pure culture of Pantoea agglomerans having all of the characteristics of FERM BP-3511 is disclosed. The characteristics include morphology, growth, physiological, carbon utilization sources and various enzymatic tests, as well as the required production of a lipopolysaccharide and all of these characteristics have been identified for the culture of P. agglomerans. In addition the lipopolysaccharide has a dominant molecular weight of 6,500.+-.2,500 as determined by SDS-PAGE method, 2.+-.phosphorus, 5.+-.hexosamines and 2.+-.1 2-keto-3-deoxyoctonate per molecular weight of 5,000. The specific enzymatic tests involve such enzymes as lysin decarboxylase, arginine dihydroxylase, phenylalanine deaminase and ornithine decarboxylase. Further, a test for utilization of malonate by the culture is disclosed.

Abstract: Antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain lipopolysaccharide (LPS) representatives which have the following physical properties:LPS1 Dominant molecular weight: 5,000.+-.1,000 as determined by SDS-PAGR method______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 9 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.); ______________________________________LPS2 Dominant molecular weight: 6,500.+-.2,500 as determined by SDS-PAGR method ______________________________________ Phosphorus number: 1 to 2/5,000 (m.w.) Hexosamine number: 7 .+-. 1/5,000 (m.w.) KDO number: 1 to 2/5,000 (m.w.); and ______________________________________LPS3 Dominant molecular weight:6,500.+-.2,500 as determined by SDS-PAGE method ______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 5 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.

Abstract: A limulus test-positive plant glycolipid having the following properties: molecular weight: 8000 .+-.1000 by SDS electrophoresis, number of phosphorous not less than 1/mol; number of hexosamine 6 .+-.2/mol; number of fatty acids 6 .+-.2/mol is effective in the stimulation of osteogenesis, oviposition and shell strength improvement in animals. The glycolipid may be administered as a composition comprising an effective amount of the glycolipid in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, the immune system of the animal is favorably stimulated.

Abstract: Novel LPS having the following physical properties, novel bacilli providing those LPS, and novel immunity stimulators, anagesics, and antiwithdrawal agents, and novel veterinary immunity stimulators, analgesics, and antiwithdrawal agents containing LPS selected from the group consisting of those LPSs and mixtures thereof.LPS1 Dominant molecular weight: 5,000.+-.1,000 as determined by______________________________________ SDS-PAGE method ______________________________________ Phosphorus number: 2 .+-. 1/5,000 (m.w.) Hexosamine number: 9 .+-. 1/5,000 (m.w.) KDO number: 2 .+-. 1/5,000 (m.w.) ______________________________________LPS2 Dominant molecular weight: 6,500.+-.2,500 as determined by ______________________________________ SDS-PAGE method ______________________________________ Phosphorus number: 1 to 2/5,000 (m.w.) Hexosamine number: 7 .+-. 1/5,000 (m.w.) KDO number: 1 to 2/5,000 (m.w.) ______________________________________ LPS3 Dominant molecular weight: 6,500.+-.

Abstract: An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED.sub.50 is 0.

Abstract: A limulus test-positive plant glycolipid having the following properties:molecular weight: 8000.+-.1000 (SDS electrophoresis)number of phosphorus: not less than 1/mol.number of hexosamine: 6.+-.2/mol.number of fatty acid: 6.+-.2/mol is effective in the stimulation of osteogenesis, oviposition and shell strength improvement in animals. The glycolipid may be administered as a composition comprising an effective amount of said glycolipid in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, the immune system of said animal is favorably stimulated.

Abstract: Novel DNA's encoding variants of TNF which comprise substitutions and/or deletions in the n-terminal portion of the TNF polypeptide resulting in enhanced cytotoxic activity are taught.

Abstract: Novel condurango glycoside compounds, antitumor agents comprising them and processes for their preparation, compositions containing them and methods of treating tumor with them are disclosed herein in which the novel condurango glycoside compounds are represented by the following formula (I): ##STR1## where X together with the 13 and 14 position carbon atoms is a group selected from the group consisting of ##STR2##

Abstract: New extracts of Marsdenia cundurango Reichenbach fil., processes for preparing them, antitumor agents comprising them, compositions containing them and methods of treating tumor with them are described herein in which the extracts consist essentially of the portion of Marsdenia cundurango Reichenbach fil. which is soluble in lower alcohols and in chlorinated hydrocarbons other than carbon tetrachloride and insoluble in carbon tetrachloride or aromatic hydrocarbons.

Abstract: New extracts of Marsdenia cundurango Reichenbach fil., processes for preparing them, antitumor agents comprising them, compositions containing them and methods of treating tumor with them are described herein in which the extracts consist essentially of the portion of Marsdenia cundurango Reichenbach fil. which is soluble in lower alcohols and in chlorinated hydrocarbons other than carbon tetrachloride and is insoluble in aliphatic hydrocarbons.